{"entity":{"id":"nct07439094","kind":"trial","name":"A First-in-Human Study of CKD-703 in Advanced Solid Tumors and Non-Small Cell Lung Cancer","aka":[],"tldr":"A phase 1/2 trial of CKD-703 in non-small-cell lung cancer, run by Chong Kun Dang Pharmaceutical, now recruiting.","summary":"A First-in-Human Study of CKD-703 in Advanced Solid Tumors and Non-Small Cell Lung Cancer is a phase 1/2 interventional study registered as NCT07439094 by Chong Kun Dang Pharmaceutical, with 140 participants planned, started 2026-04-16 and due to reach its primary completion in 2029-12. Interventions recorded: CKD-703.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07439094","url":"https://clinicaltrials.gov/study/NCT07439094"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07439094","phase":"1/2","setting":"A First-in-Human, Multicenter, Open-Label, Phase 1/2a Study to Evaluate the Safety, Efficacy and Pharmacokinetics of CKD-703 in Advanced c-Met Expressing Solid Tumors, and in MET Amplified and c-Met Overexpressing Non-Small Cell Lung Cancer","sponsor":"Chong Kun Dang Pharmaceutical","enrolled":140,"outcomes":[]},"route":"/trials/nct07439094/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}]}}